title: Optic neuropathy in patients with glioblastoma receiving bevacizumab.
authors: Departments of Neurological Surgery,University of Virginia, Charlottesville, VA 22908, USA.
authors: J H
authors: JH
authors: Sherman
authors: D G
authors: DG
authors: Aregawi
authors: A
authors: A
authors: Lai
authors: H M
authors: HM
authors: Fathallah-Shaykh
authors: P J
authors: PJ
authors: Bierman
authors: K
authors: K
authors: Linsky
authors: J M
authors: JM
authors: Larner
authors: S A
authors: SA
authors: Newman
authors: D
authors: D
authors: Schiff
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000139:chemically induced*; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab